Proteomics Market

The proteomics market is anticipated to grow significantly, with projections indicating an increase from US$ 34.56 billion in 2024 to US$ 85.91 billion by 2031, reflecting a CAGR of 11.9% from 2025 to 2031.

Analyst Perspective:

This report outlines growth opportunities based on current trends in the proteomics market and their expected effects during the forecast period. Proteomics involves the extensive study of proteomes, which are collections of proteins produced by a biological entity. A proteome is dynamic, varying from one cell to another and changing over time. It provides insights into the underlying transcriptome, which encompasses all messenger RNA molecules in an organism. Various factors, beyond just gene expression levels, affect protein activity. The applications of proteomics are vast, and the market is projected to expand significantly due to rising demand for personalized medicine and increased research and development in the field. However, stringent regulatory requirements and a shortage of skilled professionals may hinder market growth.

Market Overview:

Proteomics is the comprehensive study of protein structures and functions. It includes the rapidly advancing area of disease proteomics, which seeks to identify proteins associated with human diseases and understand how their expression, structure, and function contribute to disease. Key drivers of growth in the proteomics market include the rising incidence of cancer and other diseases. Ongoing proteomics research aids healthcare professionals in understanding protein behavior in dynamic environments, such as in cancer patients, by providing critical biomarker information. Moreover, advancements in nano proteomics are expected to positively influence market growth in the coming years.

Strategic Insights Market Driver: Rising Incidence of Chronic Diseases Fuels Market Expansion

The increasing prevalence of chronic diseases, including cancer, respiratory illnesses, chronic kidney disease (CKD), and cardiovascular diseases (CVDs), is a significant factor anticipated to drive market growth. For instance, Globocan reported approximately 19.3 million new cancer cases globally in December 2020, with 10 million cancer-related deaths. Cardiovascular diseases are also among the leading causes of death worldwide, with the WHO (2021) noting that these diseases account for 41 million deaths annually. The rising incidence of life-threatening diseases is driving demand for personalized therapies, which positively impacts the industry.

As a significant portion of the global population battles cancer, the demand for effective treatments has surged. Numerous breakthroughs are being made in life sciences, with the characterization of human proteins marking a significant advancement in biomedicine. Evaluating gene expression at the proteome level is crucial. Ongoing research and development in this area are expected to lead to substantial growth in the proteomics market, as this technique can yield vital biological insights that enhance our understanding of cancer biology. The increasing prevalence of chronic diseases further amplifies the demand for proteomics.

Segmental Analysis:

The analysis of the proteomics market has been conducted by examining the following segments: product & service, application, and end user.

In terms of product & service, the proteomics market is categorized into instrumentation technologies, reagents & consumables, and software & services. The reagents & consumables segment dominated the market in 2022 and is projected to achieve the highest CAGR of 14.1% from 2022 to 2030. This growth is attributed to the increasing utilization of reagents, kits, consumables, and strips for studying various biological materials in research institutions and universities. Additionally, government initiatives supporting proteomics and genomics, along with heightened research activities in disease diagnostics, are expected to drive market growth. Furthermore, advancements in sophisticated instruments, such as 3D electrophoresis protein analyzers, which enhance the speed, efficiency, and productivity of biological research, will also contribute to market expansion.

By application, the market is segmented into clinical diagnostics, drug discovery & development, and others. The clinical diagnostics segment held the largest share of the proteomics market in 2022, as researchers and clinicians frequently utilize protein analysis to identify disease biomarkers for early risk factor detection. Proteomics-based diagnostics can also uncover potential protein transcription regulation, aiding in the identification and prognosis of malignancies.

Regarding end users, the proteomics market is divided into pharmaceutical & biotechnology companies, research & clinical laboratories, hospitals, and others. The pharmaceutical & biotechnology companies segment accounted for the largest market share in 2022. However, the research & clinical laboratories segment is expected to experience the highest CAGR of 14.5% from 2022 to 2030. Increased R&D funding from pharmaceutical and biotechnology firms aimed at developing innovative drugs is likely to drive demand for proteomics services. Additionally, the need for enzymes, reagents, and kits is being fueled by heightened research and development activities, ongoing proteomics studies targeting various life-threatening diseases, and increased life science projects in academic and research settings.

Regional Analysis:

The proteomics market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North American market was valued at US$ 11.95 billion in 2022 and is projected to reach US$ 33.56 billion by 2030, with an expected CAGR of 13.8% from 2022 to 2030. Key factors driving market growth in this region include increased investments in structure-based drug design, demand for high-quality research tools for data reproducibility, and growth in omics research. There is a focus on developing personalized treatments, and partnerships among major regional companies also contribute to market expansion. For example, Thermo Fisher Scientific Inc. and Symphogen have collaborated to create verified platform processes for the optimized characterization and quality monitoring of complex therapeutic proteins. Numerous protein therapies are currently undergoing clinical trials for cancer, infections, immunological disorders, age-related diseases, and other conditions. Additionally, proteomics research is thriving in the US, driven by the high incidence of inherited diseases like Alzheimer's and infectious diseases such as malaria and tuberculosis in the region.

The Asia Pacific proteomics market is expected to exhibit the fastest CAGR of 14.3%. This region, particularly countries like India and China, boasts a substantial pharmaceutical industry, with China serving as a hub for pharmaceutical manufacturing. The anticipated market growth in this region is attributed to the presence of highly functional manufacturing units and contract manufacturing facilities. Furthermore, a large population susceptible to cancer and other infectious diseases, extensive use of proteomics in diagnosing genetic disorders, and increased R&D spending and social programs are expected to drive the demand for proteome-based disease diagnosis, thereby enhancing market growth.

Proteomics Market Report Scope Key Player Analysis:

Key players profiled in the proteomics market report include Proteome Sciences, Biognosys, Creative Proteomics, Shantani, Olink, SomaLogic Operating Co., Inc., QUANTUM-SI INCORPORATED, Proteomics International, Promise Proteomics, SCIEX, Illumina, Inc., and Thermo Fisher Scientific Inc.

Recent Developments:

Companies in the proteomics market are pursuing mergers and acquisitions as key growth strategies. Recent developments in the market include:

1. In June 2022, SomaLogic and Illumina, Inc. announced a joint development agreement to utilize the SomaScan Proteomics Assay on Illumina's current and future high-throughput next-generation sequencing (NGS) platforms, accelerating next-generation sequencing in the rapidly growing proteomics market.
2. In May 2022, Proteomics International Laboratories Ltd secured US$ 13,516 in funding to facilitate the production of its PromarkerD clinical diagnostic in Australia, the first diagnostic predictive test for diabetes-related kidney disease. This initiative aims to foster new health innovations and advance discoveries toward proof-of-concept and commercialization that address significant health challenges and maximize entrepreneurial potential.